Document is current
Any future updates will be listed below
-
Authors
Choi, Siyoung
Whitman, Matthew A. https://orcid.org/0000-0002-5399-5318
Shimpi, Adrian A. https://orcid.org/0000-0002-0782-0496
Sempertegui, Nicole D. https://orcid.org/0000-0001-9762-9419
Chiou, Aaron E. https://orcid.org/0000-0002-3762-9385
Druso, Joseph E.
Verma, Akanksha
Lux, Stephanie C.
Cheng, Zhu
Paszek, Matthew
Elemento, Olivier https://orcid.org/0000-0002-8061-9617
Estroff, Lara A. https://orcid.org/0000-0002-7658-1265
Fischbach, Claudia https://orcid.org/0000-0002-9368-0150
-
Funding
Funding for this research was provided by:
Human Frontier Science Program (RGP0016/2017)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1U54CA210184)
National Science Foundation (DGE-1650441, DGE-1650441)
- License Information
-
More Information
Article History
Received: 29 April 2022
Accepted: 30 June 2023
First Online: 7 August 2023
Competing interests
: O.E. was supported by Janssen, J&J, Astra-Zeneca, Volastra and Eli Lilly research grants. He is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech, and a paid scientific advisor to Champions Oncology and Pionyr Therapeutics. The other authors declare no competing interests.
